Merck delays Arcoxia filing
Merck, one of the biggest US drug companies, said it would not refile an expanded US approval application for Arcoxia, anew arthritis drug, until the second half of next year. The news dashed hopes
Merck, one of the biggest US drug companies, said it would not refile an expanded US approval application for Arcoxia, anew arthritis drug, until the second half of next year. The news dashed hopes